AI Article Synopsis
- The study explored how systemic oxytocin (OT) affects implant integration in osteoporotic rats after they underwent ovariectomy to model osteoporosis.
- Twenty rats were divided into an experimental group receiving daily OT injections and a control group getting a placebo, with implants inserted into their femurs after a 12-week osteoporosis model was established.
- Results showed that the OT group had significantly better bone integration metrics compared to the control group, suggesting OT may help enhance healing and integration of implants in osteoporotic conditions.
Article Abstract
Objective: This study investigated the effects of systemic administration of oxytocin (OT) in osteoporotic rats on implant osseointegration.
Methods: Twenty rats were randomly assigned to the control and experimental groups. Initially, the rats underwent bilateral ovariectomy. After 12 weeks, an osteoporosis model was established. Each rat received an implant at the distal and middle femoral metaphysis. Simultaneously, systemic administration was conducted with one group receiving subcutaneous injection of OT (1 mg·kg⁻¹ per day), whereas the other group received placebo injection. After treatment for 4 weeks, another surgery was conducted to remove the thigh bones from the rats containing the implants for an eight-week observation. With the employment of micro-CT, histological observation and push-out test, osseointegration was evaluated. While the rats received thigh-bone removal surgery, another surgery was conducted to remove the tibia metaphysis from the rats of both groups to perform histological observation and micro-CT inspection.
Results: The trabecular bone of tibial samples was intensive and formed woven mesh structure in the experimental group compared with the control group. In the experimental group, the relative bone volume/tissue volume surrounding the implant, the bone contact ratio, and the maximum push-out force of the implant were 0.35%±0.06%, 67.25%±9.06%, and (70.32±10.91) N, respectively, the corresponding values were 0.11%±0.02%, 43.25%±7.01% and (21.65±4.36) N in the control group, and the experimental group increased significantly compared with the control group (P<0.05).
Conclusions: Systemic administration of OT cannot only antagonize the negative effects of osteoporosis but can also promote implant healing and osseointegration of pure titanium implants.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7030010 | PMC |
| http://dx.doi.org/10.7518/hxkq.2016.04.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells.
Cytotherapy
January 2025
Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada. Electronic address:
The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought on approved MSC clinical products in the United States. While other jurisdictions-including Europe, Japan, India, and South Korea-have marketed autologous or allogeneic MSC products, the United States has lagged in its approval. The sponsor's significant efforts and investments, working closely with the FDA addressing concerns regarding clinical efficacy and consistent MSC potency through an iterative process that spanned several years, was rewarded with this landmark approval.
View Article and Find Full Text PDFLong-Term Outcomes of Radiation Monotherapy Versus Combined Radiation Monotherapy + Hormone Therapy in Low-Risk Early-Stage Breast Cancer Patients 70 Years or Older After Breast-Conserving Surgery.
Int J Radiat Oncol Biol Phys
January 2025
Providence Swedish Cancer Institute, Seattle, Washington.
Purpose: Standard therapy for breast cancer after breast-conserving surgery is radiation therapy (RT) plus hormone therapy (HT). For patients with a low-risk of recurrence, there is an interest in deescalating therapy.
Methods And Materials: A retrospective study was carried out for patients treated at the Swedish Cancer Institute from 2000 to 2015, aged 70 years or older, with pT1N0 or pT1NX estrogen receptor-positive and ERBB2-negative unifocal breast cancer without positive surgical margins, high nuclear grade, or lymphovascular invasion.
CXCR4 antagonist-loaded nanoparticles reprogram the tumor microenvironment and enhance immunotherapy in hepatocellular carcinoma.
J Control Release
January 2025
Institute of Biomedical Engineering, National Tsing Hua University, Hsinchu 30013, Taiwan; Department of Chemistry, National Tsing Hua University, Hsinchu 30013, Taiwan. Electronic address:
Hepatocellular carcinoma (HCC) is a leading cause of cancer death that has limited treatment options for advanced stages. Although PD-1 inhibitors such as nivolumab and pembrolizumab have been approved for advanced HCC treatment, their effectiveness is often hampered by the immunosuppressive tumor microenvironment (TME), which is due to hypoxia-driven CXCL12/CXCR4 axis activation. In this study, we developed 807-NPs, lipid-coated tannic acid (TA) nanoparticles that encapsulate BPRCX807, a potent CXCR4 antagonist to target HCC.
View Article and Find Full Text PDFDevelopment of a transdermal gel for reversible male contraception.
Contraception
January 2025
Division of Endocrinology, Department of Medicine, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California; Clinical and Translational Science Institute, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California.
While there are several easy-to-use reversible female contraceptives, little is available for men. Introduction of novel, cost-effective male contraceptives could have important downstream global health and economic benefits. Currently, nearly half of all pregnancies globally are unintended, with many resulting in unsafe abortions, a significant burden for women and families in many countries.
View Article and Find Full Text PDFApixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial.
Lancet Neurol
February 2025
Department of Medicine, McMaster University, Population Health Research Institute, Hamilton, ON, Canada.
Background: People with subclinical atrial fibrillation are at increased risk of stroke, albeit to a lesser extent than those with clinical atrial fibrillation, leading to an ongoing debate regarding the benefit of anticoagulation in these individuals. In the ARTESiA trial, the direct-acting oral anticoagulant apixaban reduced stroke or systemic embolism compared with aspirin in people with subclinical atrial fibrillation, but the risk of major bleeding was increased with apixaban. In a prespecified subgroup analysis of ARTESiA, we tested the hypothesis that people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack, who are known to have an increased risk of recurrent stroke, would show a greater benefit from oral anticoagulation for secondary stroke prevention compared with those without a history of stroke or transient ischaemic attack.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!